INVO Bioscience Q1 revenue up 353% to $1.58M, net loss narrows to $1.6M

INVO Fertility, Inc.

2024-Q1 EPS reported -$0.42 revenue$1,576,286

Revenue $1,576,286, up 353% YoY from $348,025; clinic revenue up 417% to $1.54M.
Net loss $(1.6) million vs $(2.6) million; Adjusted EBITDA improved to $(0.5) million from $(1.7) million.
Merger with NAYA Biosciences pending; shareholders to receive 7.3333 INVO shares per NAYA share (~18.15M shares total).
NAYA has provided $906k in Series A Preferred Stock financing towards $5M minimum condition for merger.
Management expects to reach break-even on current operations (ex-merger) in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INVO Fertility, Inc. reported financial results for the first quarter of 2024.

Period: the first quarter of 2024
Result: reported results

Exact text from the filing

On May 15, 2024, INVO Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the period ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

INVO Fertility, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-019958

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.